Pfizer Inc.(PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest News & Analysis
Pfizer Inc. Eliquis Pricing Strategy and Financial Impact Analysis | Monexa AI
Explore Pfizer's Eliquis direct-to-patient pricing strategy, its financial impact, competitive positioning, and dividend sustainability backed by latest data.
Pfizer Inc. Growth Strategy and Financial Analysis: Oncology, AI, and Market Position
Explore Pfizer's strategic oncology expansion, AI innovation, and financial health amid challenges like litigation and COVID-19 revenue declines.
Pfizer Inc. Financial Update: Oncology Pipeline, Patent Challenges, and Dividend Sustainability
Pfizer advances its oncology pipeline with promising candidates and biomarker validation while navigating patent cliffs and maintaining a strong dividend yield.
Pfizer Inc. (PFE) Latest Financial and Strategic Update: Earnings, Debt, and Market Position
Pfizer Inc. reports strong earnings growth and strategic shifts in 2024, with rising revenues, increased R&D investment, and evolving debt structure shaping its market stance.
Pfizer Inc. Dividend Sustainability and Financial Health Analysis - Monexa AI
Pfizer's high dividend yield at 6.7% is supported by cash flow but challenged by payout ratio over 120%, legal risks, and competitive pressures.
Pfizer Inc. Patent Appeal and Financial Overview: Strategic Implications for Investors - Monexa AI
Detailed analysis of Pfizer's patent appeal against Moderna, financial performance, and strategic outlook shaping its competitive position in the mRNA vaccine market.
Pfizer Inc. (PFE) Dividend Sustainability and Pipeline Growth: A Data-Driven Market Analysis
Analyze Pfizer's dividend sustainability, financial health, pipeline strategy, and market positioning amid patent cliffs and legal challenges in this comprehensive update.
Pfizer Inc. Strategic Shift with $6.7B Arena Pharma Acquisition and Cannabis Market Expansion
Pfizer's $6.7B acquisition of Arena Pharmaceuticals marks a key pivot into medical cannabis, backed by robust financials and a promising cannabinoid pipeline.
Pfizer Inc. Market Update: Vaccine Delay Probe, Financial Strength, and Strategic Outlook
Pfizer faces a House probe over COVID-19 vaccine timing amid strong financials and strategic moves. Analyze market impact, financials, and future outlook.
Pfizer's Hympavzi: A Data-Driven Catalyst for Hemophilia Treatment
Pfizer's Hympavzi, with its 93% bleeding reduction in trials, signals a strategic pivot and potential financial turnaround for the pharma giant.
Pfizer (PFE): Innovation, Litigation, and Market Dynamics in 2025
Pfizer navigates a complex landscape in 2025, balancing new drug successes and the Seagen acquisition with significant legal challenges.
Pfizer's Strategic Oncology Push Amidst Mounting Legal Headwinds
Pfizer navigates oncology growth, fueled by Seagen, against legal challenges, vaccine policy shifts, and a high dividend yield raising sustainability questions.
Pfizer ([PFE](/dashboard/companies/PFE)) Navigates Legal Scrutiny & Oncology Growth
Pfizer ([PFE](/dashboard/companies/PFE)) faces fiduciary duty probes while advancing its oncology pipeline. Learn how legal challenges and strategic growth impact its market position.
Pfizer (PFE): Navigating Patent Expirations and Regulatory Shifts
Pfizer faces a critical juncture in 2025, navigating significant patent expirations and a volatile regulatory landscape following recent vaccine panel changes.
Pfizer ([PFE](/dashboard/companies/PFE)) Financial Analysis: Cost Control, Pipeline & Dividend Outlook
Deep dive into Pfizer's latest financials and strategy, analyzing recent earnings, cost controls, oncology pipeline, patent challenges, and dividend sustainability.
Pfizer (PFE): Navigating Legal Hurdles, Stock Volatility, and Future Growth
Pfizer (PFE) faces challenges but the GSK lawsuit resolution and cost-cutting offer upsides. High dividend yield may attract investors, but volatility and tariffs warrant caution.
Pfizer (PFE): ABRYSVO Approval, Tariff Risks, and Dividend Dilemma
Pfizer Inc. (PFE) navigates EU approval of ABRYSVO, tariff threats, and dividend sustainability concerns amid ETF shifts. A deep dive into PFE's strategic response.
Pfizer (PFE): Strategic Shift, Pipeline Focus, and Growth Outlook
Pfizer's strategic shift, pipeline focus, and dividend appeal analyzed. Learn how these factors shape its growth outlook and investment potential.
Pfizer (PFE): Strategic Shifts, Dividend Outlook, and Growth
Pfizer (PFE) navigates strategic shifts, a compelling dividend, and growth challenges. This analysis explores valuation, market sensitivity, and strategies to mitigate trade war risks.
Pfizer's Strategic Reset: Haleon Divestiture, China Expansion, and Dividend Outlook
Pfizer navigates strategic shifts: Haleon divestiture, China expansion, and dividend sustainability in a dynamic pharmaceutical landscape.
Pfizer (PFE): Sales, China, and Apretude Strategy Analysis
Pfizer (PFE) navigates post-pandemic market via sales revamp, China focus, Apretude. Financial analysis reveals fluctuating profitability. Valuation gap suggests undervaluation. Investors monitor catalysts.
Pfizer (PFE): Oncology Breakthroughs, Financial Resilience, Dividend
Pfizer Inc. (PFE) navigates oncology breakthroughs, financial resilience, and dividend sustainability amidst challenges. Strategic collaborations and cost-cutting are crucial.
Pfizer Inc.: Intraday Updates and Key Developments
Pfizer intraday update reveals robust revenue growth, dividend strength and legal challenges shaping its strategic trajectory.
Pfizer's Strategic Shift: Oncology Focus & Vaccine Pipeline
Pfizer strategically focuses on oncology via collaborations like Summit Therapeutics, navigating regulatory changes and new coronavirus variants. Legal challenges and vaccine demand present risks.
Pfizer: Oncology Strategy, Regulatory Changes, and Market Outlook
Pfizer focuses on oncology via collaborations, addresses coronavirus concerns, and faces a Depo-Provera probe. Cavazzoni's CMO role could streamline approvals, while value stocks gain traction.
Pfizer's Strategic Shift: Oncology, Regulatory Expertise, and Dividend Prospects
Pfizer focuses on oncology with Ivonescimab, appoints Patrizia Cavazzoni as CMO, and navigates vaccine demand and legal challenges, maintaining investor appeal.
Pfizer's Strategic Shift: Pipeline Adjustments and Market Impact
A comprehensive, data-driven update on Pfizer Inc.'s strategic pivot, pipeline realignment, legal investigations, and market challenges.
Pfizer's Strategic Pivot: Gene Therapy Setback and Oncology Focus
Pfizer navigates strategic shifts, ending gene therapy development while focusing on oncology amid legal scrutiny, impacting investor sentiment and future prospects.
Pfizer: Navigating Oncology, Dividends, and Regulatory Challenges in 2025
A detailed data-driven update on Pfizer’s latest developments, clinical breakthroughs, and regulatory challenges affecting [PFE](/dashboard/companies/PFE).
Pfizer Faces Scrutiny Amidst Drug Developments & Headwinds
A comprehensive intraday analysis of Pfizer covering legal scrutiny, breakthrough clinical trials, dividend yields, and strategic market responses.